.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The IMPACT trial tested whether once-daily single-inhaler triple therapy could improve outcomes compared with two commonly used dual therapies in symptomatic patients with COPD and a history of exacerbations. More than 10,000 participants were randomized to fluticasone furoate/umeclidinium/vilanterol, fluticasone furoate/vilanterol, or umeclidinium/vilanterol. Triple therapy reduced the rate of moderate or severe COPD exacerbations compared with both dual regimens. The study therefore strengthened the case for inhaled triple therapy in appropriately selected patients who remain at high exacerbation risk despite maintenance treatment. At the same time, pneumonia was more frequent in the inhaled-corticosteroid-containing groups, reinforcing the need for individual risk–benefit assessment rather than automatic escalation. For practicing clinicians, the key lesson is to match inhaler intensity to phenotype and treatment history. A patient with frequent exacerbations may benefit from triple therapy, while another patient with predominantly dyspnoea and low exacerbation risk may gain more from optimized bronchodilation without added ICS exposure. The findings align closely with the conference emphasis on GOLD strategy, COPD phenotyping, and making treatment decisions using more than lung function alone.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The IMPACT trial tested whether once-daily single-inhaler triple therapy could improve outcomes compared with two commonly used dual therapies in symptomatic patients with COPD and a history of exacerbations. More than 10,000 participants were randomized to fluticasone furoate/umeclidinium/vilanterol, fluticasone furoate/vilanterol, or umeclidinium/vilanterol. Triple therapy reduced the rate of moderate or severe COPD exacerbations compared with both dual regimens. The study therefore strengthened the case for inhaled triple therapy in appropriately selected patients who remain at high exacerbation risk despite maintenance treatment. At the same time, pneumonia was more frequent in the inhaled-corticosteroid-containing groups, reinforcing the need for individual risk–benefit assessment rather than automatic escalation. For practicing clinicians, the key lesson is to match inhaler intensity to phenotype and treatment history. A patient with frequent exacerbations may benefit from triple therapy, while another patient with predominantly dyspnoea and low exacerbation risk may gain more from optimized bronchodilation without added ICS exposure. The findings align closely with the conference emphasis on GOLD strategy, COPD phenotyping, and making treatment decisions using more than lung function alone.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
